Pharma Recruitment in Belgium: The Talent Market CDMOs, CROs, and Biotechs Cannot Afford to Misread

Belgium's Pharma Services Sector: A Talent Market You Cannot Afford to Misread

Belgium punches well above its weight in global pharma services. With a combined market capitalisation of €66.8 billion among listed biotech companies as of early 2024, a 42.7% increase year-on-year, it's cemented its position as one of Europe's most consequential pharma services markets. For hiring managers, HR leaders, and executives operating within the CDMO, CRO, and biotech space, understanding how this ecosystem is structured and where the talent pressures lie is no longer optional. It's a strategic necessity.

‍

A Market Defined by Its Clusters

Belgium's pharma services strength isn't concentrated in a single city or region. It's distributed across four distinct clusters, each with its own character, capabilities, and talent dynamics.

Leuven is arguably the intellectual engine of the ecosystem. Home to one of Europe's oldest universities, it's a hotbed for research-driven startups, especially in engineering and technology. The Leuven Bio-Incubator has nurtured dozens of early-stage companies in oncology, neurology, and rare diseases, many of which graduate into serious clinical-stage organisations with urgent hiring needs. The talent base here skews towards research scientists, translational specialists, and regulatory professionals, profiles that are equally coveted by multinational pharma companies and emerging biotechs.

Ghent has evolved into a powerhouse for biomanufacturing and advanced therapies. Sanofi Belgium pioneers NANOBODY® proteins and biologics in the region, and Legend Biotech has established its first European production facility for CAR-T therapy in Ghent, citing access to the talent pool in Flanders as central to that decision. Ghent's Technologiepark-Zwijnaarde hosts a dense cluster of CDMOs, CROs, and biotech companies. Cerba Research, one of the most significant CRO players in Belgium, operates its European central laboratory from Ghent. Opened in 2024, this 23,000 square metre facility processes more than 50,000 specimens daily from 50 countries. The talent competition here is intense, particularly for bioprocess engineers, GMP manufacturing specialists, and laboratory scientists with cell and gene therapy experience.

Brussels and Walloon Brabant serve a dual function: as the headquarters of choice for multinational pharma companies requiring proximity to EU regulatory bodies, and as a growing hub for biotech innovation. The Brussels South Charleroi Biopark hosts 90 companies and three academic research centres, employing more than 3,200 people, with a concentration in cell and gene therapies, immunology, neurology, and cancer research. Walloon Brabant is home to several established CDMOs including Cenexi, located 20 km south of Brussels, which specialises in the production of sterile, highly potent injectables for oncology applications. Hiring in this corridor tends to favour regulatory affairs specialists, quality assurance professionals, and senior commercial talent.

Liège has long been associated with chemical and process manufacturing, and that heritage now underpins a growing CDMO presence. Cambrex operates a cGMP facility in the Liège region, and the city's industrial infrastructure makes it a natural location for scale-up manufacturing. BioVille in Hasselt is a hotspot for the healthcare sector, with a focus on medical technology and digital health, including e-health, artificial intelligence, and wearables. Talent across this region tends to be grounded in process chemistry, analytical sciences, and manufacturing operations, disciplines that remain persistently difficult to hire across Belgium as a whole.

‍

The Roles Driving Demand

Across all four clusters, certain functions are generating the highest recruitment pressure. Quality assurance, validation, and regulatory affairs roles are experiencing strong demand, as companies prioritise compliance expertise ahead of upcoming product launches and increasingly complex regulatory environments.

Biomanufacturing talent, particularly professionals with GMP qualifications and hands-on experience in biologics or advanced therapy manufacturing, is acutely scarce. Belgium's shift towards domestic manufacturing has been driven by CDMO development and a wave of investment in additional production capacity, but the existing candidate pool hasn't kept pace. Belgium has developed exceptional expertise in technologies such as messenger RNA, plasmid DNA, cell and gene therapy, and monoclonal and polyclonal antibodies, capabilities that create entirely new skill requirements universities are only beginning to address.

Clinical research professionals, including CRAs, project managers, and data managers, are consistently in demand across the CRO sector. Belgium's active clinical trial landscape means that experienced clinical operations talent is competed for vigorously, often across national borders.

There's also growing demand for interdisciplinary scientists who bridge science and strategy, emerging from hybrid academic-industry tracks and translational research centres. This is particularly visible in medical affairs, translational research, and business development roles within biotech companies approaching their first commercial product.

‍

The Hiring Challenges That Leaders Are Talking About

Belgium's bilingual character, and in the pharma services sector, often trilingual reality, adds a layer of complexity to talent acquisition that's frequently underestimated. Many senior roles require functional proficiency in Dutch, French, and English. Organisations based in Brussels or straddling the linguistic border face particular challenges, as the candidate pool that meets both the scientific and language requirements simultaneously is notably narrow.

High demand for experienced GMP-trained professionals, competition from major pharmaceutical companies with established presence, and a limited pool of specialised talent for advanced manufacturing processes create conditions where smaller biotechs and CDMOs frequently find themselves outgunned on compensation and brand recognition. Time-to-hire for specialist roles extends well beyond 90 days when organisations rely on direct sourcing alone, and for companies at critical junctures such as a regulatory submission, a manufacturing scale-up, or a clinical programme milestone, that delay carries real operational risk.

Retention is an equally pressing concern. Attrition spikes once signing bonuses fade, and as much as 45% of pharma services turnover occurs within the first year of employment. The wrong hire, or the wrong onboarding, loses talent that was expensive to attract.

Across Europe, job openings in biotech have risen 17% compared to last year, while candidate availability has barely grown. The largest talent gaps are in translational research, clinical bioinformatics, and scaled biomanufacturing, all areas where Belgium's ambitions are considerable.

‍

Where Vector Talent Fits In

Vector Talent works with pharma services organisations across Belgium's sector, supporting hiring across the CDMO, CRO, and biotech landscape. Our partnership with Cerba Research, whose operations are based in Flanders and whose global laboratory network spans five continents as part of the Cerba HealthCare Group, reflects the kind of work we do: placing specialist scientific and operational talent within organisations where the quality of a hire has direct consequences for clinical trial timelines, patient outcomes, and commercial performance.

Cerba Research operates as a global partner for integrated clinical trial laboratory and diagnostic solutions, working across oncology, virology, immunology, and cell and gene therapy. The talent required to deliver on that mission, including laboratory scientists, biomarker specialists, clinical operations leads, and data management professionals, represents precisely the profile that demands a recruiter with genuine sector depth.

Belgium's pharma services sector will continue to grow. The investment is real, the pipeline is substantial, and the regulatory environment, anchored by proximity to EMA networks and Belgium's well-established relationship with EU pharmaceutical policy, provides structural advantage. The variable that will determine which organisations capitalise on that growth is talent.

‍